Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

2 hours ago 2

Brendan Coffey, The Motley Fool

Sat, June 20, 2026 astatine 12:01 PM CDT 4 min read

Just a fewer days aft a well-received archetypal nationalist offering, a manager of cause developer Parabilis Medicines (NASDAQ:PBLS) bought shares successful the unfastened market.

Director Alan Sebulsky disclosed the acquisition of 17,500 shares successful aggregate open-market transactions connected June 12 and June 15, 2026, for a full information of astir $474,000, according to the SEC Form 4 filing.

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($27.06); post-transaction worth based connected June 18, 2026 marketplace adjacent ($25.85).

Key questions

How did this transaction interaction Alan Sebulsky's ownership successful Parabilis Medicines?
Following the transaction, Mr. Sebulsky's nonstop holdings remained astatine zero portion his indirect holdings, held via Apothecary Capital LLC, accrued to 30,000 shares.
Was the transaction executed astatine a premium oregon discount to caller terms levels?
The weighted-average acquisition terms of $27.06 per stock was astir 8.2% supra the June 15 marketplace adjacent of $25.85.
What is the value of the indirect ownership operation successful this filing?
All shares were acquired and held done Apothecary Capital LLC, accordant with anterior filings attributing beneficial ownership to indirect entities alternatively than idiosyncratic accounts.
Does this transaction bespeak a displacement successful trading signifier oregon capacity?
The summation successful indirect holdings follows constricted humanities activity, with the transaction representing the largest azygous reported summation to Mr. Sebulsky's indirect presumption to day and nary nonstop holdings established.

Company overview

Company snapshot

Develops cell-penetrating miniproteins (CPMPs) designed to people and neutralize cancer-causing proteins wrong crab cells.
Operates arsenic a clinical-stage biotechnology company, generating worth done the find and improvement of proprietary therapeutic candidates.
Serves oncology-focused healthcare providers and pharmaceutical partners seeking innovative crab attraction modalities.

Parabilis Medicines is simply a Cambridge, Massachusetts-based biotechnology institution specializing successful the improvement of caller cell-penetrating miniproteins for oncology applications. The institution leverages proprietary exertion to code intracellular crab targets, aiming to present differentiated therapies successful the competitory crab attraction landscape.

Read Entire Article